Opioid-free Anesthesia in VATS Lung Resection

Sponsor
Peking University People's Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04507165
Collaborator
(none)
100
1
2
23
4.4

Study Details

Study Description

Brief Summary

A comparison of incidences of postoperative opioid-related adverse effects and recovery parameters in patients undergoing video-assisted thoracoscopic surgery (VATS) lung resection receiving opioid or opioid-free general anesthesia (OFA).

Condition or Disease Intervention/Treatment Phase
  • Procedure: Paravertebral block+Anterior serratus plane block
  • Drug: opioid free anesthesia
  • Drug: opioid based anesthesia
N/A

Detailed Description

Video-assisted thoracoscopic surgery (VATS) lung resection is traditionally performed under general anesthesia with opioid-based analgesia. It is associated with higher incidences of respiratory depression, hypotension, postoperative nausea and vomiting (PONV), dizziness, constipation and urinary retention, and more severe acute postoperative pain.

The purpose of our study is to compare the opioid-free general anesthesia with the opioid-based general anesthesia with respect to the primary outcome measures of the total incidence of opioid-related adverse effects (including respiratory depression, hypotension, PONV and dizziness) and secondary outcome measures of incidence of intraoperative and postoperative cardiovascular complications, pain relief, analgesic requirement , and other postoperative recovery parameters [e.g. duration of tracheal extubation, departing from post-anaesthesia care unit (PACU), exhaust, defecation, and stay in hospital postoperatively].

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effect of Opioid-free Anesthesia on Postoperative Analgesia-related Adverse Reactions in Lung Resection With Video-assisted Thoracoscopic Access: a Randomized Double-blind Controlled Study
Anticipated Study Start Date :
Aug 1, 2020
Anticipated Primary Completion Date :
Jul 1, 2021
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: opioid-free general anesthesia

under opioid-free general anesthesia

Procedure: Paravertebral block+Anterior serratus plane block
Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by "ice cube" method 15 minutes after the procedure.
Other Names:
  • nerve block
  • Drug: opioid free anesthesia
    Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat. Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine [0.4μg/(kg.h)]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively. Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h).
    Other Names:
  • OFA
  • Active Comparator: opioid based general anesthesia

    under opioid based general anesthesia

    Procedure: Paravertebral block+Anterior serratus plane block
    Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by "ice cube" method 15 minutes after the procedure.
    Other Names:
  • nerve block
  • Drug: opioid based anesthesia
    Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus). Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively.
    Other Names:
  • Standard anesthesia
  • Outcome Measures

    Primary Outcome Measures

    1. Total incidence of opioid-related adverse effects of 2 hours, 4 hours, 6 hours, 24 hours and 48 hours postoperation [2 hours, 4 hours, 6 hours, 24 hours and 48 hours postoperation]

      The total incidence refers to the sum of the incidence of opioid-related adverse effects at 2h, 4h, 6h, 24h and 48h postoperationOpioid-related adverse effects here including respiratory depression, hypotension, PONV and dizziness.

    Secondary Outcome Measures

    1. Incidence of intraoperative cardiovascular complications [During the operation]

      Including the incidence of arrhythmia, the probability of using hyperensor and hypotensor.

    2. Incidence of postoperative cardiovascular complications [Up to 30 days postoperation]

      Including the incidence of arrhythmia, the probability of using hypertensor and hypotensor.

    3. Duration of tracheal intubation removing [Up to 2 hours postoperation]

      From anesthetic discontinuance to tracheal extubation

    4. Duration of departing from PACU [Up to 4 hours postoperation]

      From tracheal extubation to Aldrete score>9. Aldrete score is the standard for departing from PACU which includes five contents to evaluate: activity, breath, blood pressure, state of consciousness and oxygen saturation by pulse oximetry (SpO2). 2 point in total for each content. 2 point refers to the best state, whereas 0 point refers to the worst state. When a patient's total score greater than 9 who will be transferred out of PACU.

    5. Pain severity [2 hours, 4 hours, 6 hours, 24 hours and 48 hours after tracheal extubation]

      Using 0-10 numerical rating scale (NRS). The NRS score is ranged from 0 to 10. 0 means without pain. 1-3 means mild pain. 4-6 means moderate pain. 7-9 means severe pain. 10 means intense pain and can't bear.

    6. Dosage of opioids [2 hours, 4 hours, 6 hours, 24 hours and 48 hours after tracheal extubation]

      Total dosage of opioids postoperation

    7. Flatus time [Up to 48 hours postoperation]

      From the operation finished to first-time exhaust

    8. Defecation time [Up to 48 hours postoperation]

      From the operation finished to first-time defecation

    9. Postoperative duration of stay in hospital [30 days postoperation]

      The duration when patients stay in hospital after surgery.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Undergoing VATS lung resection.

    • American Society of Anesthesiologists (ASA) physical status I-II.

    • Agreed to participate in the trial.

    Exclusion Criteria:
    • Pregnant women

    • ASA phase III or above.

    • Undergoing emergency surgery.

    • Planning for thoracotomy.

    • Adults protected by law (under judicial protection, guardianship or supervision), people who deprived of their liberty.

    • Patients who have received general anesthesia.

    • Atrioventricular block, sinus node block or intraventricular block.

    • Sinus bradycardia (heart rate is less than 60 beats/min).

    • Preoperative hypotension (systolic blood pressure is less than 90mmHg)

    • Combined with urolithiasis, Meniere syndrome, and vertebral artery stenosis

    • Combined with cerebrovascular disease.

    • Contraindication to NSAIDs drug.

    • Allergic to anesthetics.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Peking University People's Hospital Beijing Beijing China 100044

    Sponsors and Collaborators

    • Peking University People's Hospital

    Investigators

    • Principal Investigator: Feng Yi, MD,PhD, Peking University People's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Yi Feng, MD, Chief of the Anesthesiology Department, Peking University People's Hospital
    ClinicalTrials.gov Identifier:
    NCT04507165
    Other Study ID Numbers:
    • 2020PHB031
    First Posted:
    Aug 11, 2020
    Last Update Posted:
    Aug 11, 2020
    Last Verified:
    Aug 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Yi Feng, MD, Chief of the Anesthesiology Department, Peking University People's Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 11, 2020